<DOC>
	<DOC>NCT01870674</DOC>
	<brief_summary>Study to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics(PK/PD)of YH12852 after oral administration in healthy subjects</brief_summary>
	<brief_title>Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>healthy male/female aged 19 to 45 with body mass index(BMI) between 18 and 25kg/m2 Subject who has no congenital, chronic disease and disease symptoms in medical examination result Subject who is judged to be eligible by principal investigator or subinvestigator according to various reasons including their abnormal test results(clinical laboratory test, 12lead ECG etc) Subjects who has signed a written informed consent voluntarily,prior to any procedure, using a form that is approved by the local Institutional Review Board after detail explanation of the purpose, contents, and characteristic of the drug Subject who has history or presence of clinically significant diseases in liver, kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system, blood tumor, cardiovascular, urinary system, and mental disorder Subject who is hypersensitive to components contained in YH12852 or prucalopride or aspirin/antibiotics like drugs Medical history of gastrointestinal disease or acid restraining surgery, gastric/ esophagus surgery(excluding appendectomy, hernia surgery) Clinically significant abnormal values in diagnostic check within 28 days before the treatment(&gt;1.25 fold of normal upper limit in the levels of AST or ALT, &gt;1.5 fold of normal upper limit in the levels of Total bilirubin, &lt; 80ml/min of CockcroftGault used creatinine clearance Subject has over QTc interval of 550 ms or PR interval of 210 ms or QRS interval of 120 ms or QT interval of 500 ms on baseline 12lead ECG, as determined by the Investigator Subject who had taken usual dose of any prescription drugs within 14 days before the treatment or who had used usual dose of OTC drugs within 7 days before the treatment Subject who participated in another clinical trail within 2 months before enrolling in this study subject who donated whole blood within 2 months or component blood within 1 month before the treatment Medically unacceptable contraception used during the clinical trial Subject who drank over 30g/day or were detected alcohol positive on test Subject who stopped smoking within 3 months before the treatment or weren't able to stop smoking during the hospitalization Subject who had a beverage containing caffeine during the hospitalization Subjects with clinically significant observations considered as unsuitable based on medical judgment by investigators</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>